News
-
-
-
-
-
PRESS RELEASE
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic reports positive long-term data from phase 2 EMPhASIS Trial of Vidofludimus Calcium in relapsing-remitting multiple sclerosis, showing favorable safety & tolerability profile up to 5.5 years -
-
-
-
-